Spencer Feldman

Gotistobart improved responses and survival versus docetaxel in pretreated squamous NSCLC, offering a potential chemo-free option with durable benefit in some patients.

A tongue cancer survivor and her oncologist discuss lasting side effects, daily management, self-advocacy and emerging treatment approaches.

Libtayo improved survival and safety outcomes vs chemotherapy in advanced NSCLC, with 23% of patients alive at six years in the EMPOWER-Lung 1 trial.

New ELCC 2026 data show longer survival, better brain metastases control and more personalized treatment options for patients with lung cancer.

Early detection and grade-based care help manage immunotherapy toxicities, with tailored approaches for skin, gastrointestinal and cardiac side effects.

AI is being used across cancer care for prevention, diagnosis, treatment, survivorship and end-of-life support, improving efficiency while posing deskilling and cognitive risks.

Black patients with early-stage lung cancer were less likely to receive curative treatment than White patients, despite all having Medicare coverage, study finds.

Functional precision medicine may help guide faster, more personalized treatment decisions in pediatric brain tumors by testing therapies directly on a patient’s tumor cells.

New FDA approvals target mutations in lung cancer, improving outcomes, while clinicians refine strategies to manage immunotherapy-related side effects.

Keytruda plus weekly paclitaxel improved overall and progression-free survival in platinum-resistant ovarian cancer in the phase 3 KEYNOTE-B96 trial.

An expert explains how immunotherapy, targeted therapy and tumor testing are expanding treatment options for patients with gynecologic cancers.

Only about 0.01% of biologic drugs reach glioblastoma tumors, but convection-enhanced delivery bypasses the barrier to deliver therapy directly to the brain.

Dr. Jonathan W. Friedberg says long-term data show 42% of treated follicular lymphoma patients achieved functional cure with chemoimmunotherapy.

Resilience programs using mindfulness and cognitive behavioral strategies help cancer survivors manage their fear and stress, as well as adjust after treatment.

Common myths about cervical cancer and HPV may discourage screening. Experts say vaccination helps but does not replace regular testing.

FDA approvals, survival gains and equity research led February’s top gynecologic cancer stories, alongside a survivor Q&A on mental health.

February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and survivorship lung health.

Four new and ongoing lung cancer trials are enrolling patients, offering options in first-line and previously treated NSCLC settings.

Overview of nodular sclerosis Hodgkin lymphoma, including diagnosis, staging, treatment options by stage and possible side effects.

Subcutaneous Rybrevant plus Keytruda led to a 56% response rate in recurrent or metastatic head and neck cancer in OrigAMI-4.

FDA approved Hernexeos for untreated HER2-mutant NSCLC after 76% of patients had tumor shrinkage in clinical trial data.

The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after immunotherapy and platinum.

FDA removal of an exclusion allows Yescarta use in primary CNS lymphoma, showing safety and strong efficacy in relapsed disease.

Thsi overview explains mesothelioma staging, diagnosis, side effects and treatment options from frontline through later lines to guide patient discussions.

FDA approves Calquence with Venclexta as a first-line option that improved progression-free survival compared with standard chemo in adults with CLL or SLL.

App-based self-acupressure improved fatigue and quality of life for women with ovarian cancer in a phase 3 trial, with benefits lasting to 24 weeks.

This device detects and characterizes lesions on low-dose CT scans, helping patients with cancer get faster, tailored care and avoid unnecessary procedures.

Study finds survival was similar during ovarian cancer trials, but gaps returned after, underscoring need for broader, more inclusive enrollment.

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control.

Black patients were underrepresented in ovarian cancer trials and had lower overall survival than White patients in a pooled analysis of 1,903 participants.